Joshua Pink
Joshua Pink
Research Fellow in Health Economics, University of Warwick
Verified email at warwick.ac.uk
Title
Cited by
Cited by
Year
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
J Pink, S Lane, M Pirmohamed, DA Hughes
Bmj 343, 2011
2152011
Autologous chondrocyte implantation in the knee: systematic review and economic evaluation
H Mistry, M Connock, J Pink, D Shyangdan, C Clar, P Royle, R Court, ...
NIHR Journals Library, 2017
832017
Cost‐effectiveness of pharmacogenetics‐guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation
J Pink, M Pirmohamed, S Lane, DA Hughes
Clinical Pharmacology & Therapeutics 95 (2), 199-207, 2014
632014
Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: systematic review and …
P Auguste, A Tsertsvadze, J Pink, N McCarthy, P Sutcliffe, A Clarke
BMC infectious diseases 17 (1), 200, 2017
562017
Folate Augmentation of Treatment--Evaluation for Depression (FolATED): randomised trial and economic evaluation.
E Bedson, D Bell, D Carr, B Carter, D Hughes, A Jorgensen, H Lewis, ...
Health Technology Assessment (Winchester, England) 18 (48), vii, 2014
412014
Dementia: assessment, management and support: summary of updated NICE guidance
J Pink, J O’Brien, L Robinson, D Longson
bmj 361, 2018
382018
First steps: study protocol for a randomized controlled trial of the effectiveness of the Group Family Nurse Partnership (gFNP) program compared to routine care in improving …
J Barnes, D Aistrop, E Allen, J Barlow, D Elbourne, G Macdonald, ...
Trials 14 (1), 285, 2013
35*2013
Parkinson’s disease: summary of updated NICE guidance
G Rogers, D Davies, J Pink, P Cooper
Bmj 358, j1951, 2017
342017
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation
J Pink, M Pirmohamed, DA Hughes
Clinical Pharmacology & Therapeutics 94 (2), 269-276, 2013
272013
Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high …
P Auguste, A Tsertsvadze, J Pink, F Seedat, T Gurung, K Freeman, ...
Health Technology Assessment 20 (38), 1-678, 2016
262016
Chronic obstructive pulmonary disease: diagnosis and management: summary of updated NICE guidance
NS Hopkinson, A Molyneux, J Pink, MC Harrisingh
Bmj 366, 2019
232019
Mechanism-based approach to the economic evaluation of pharmaceuticals
J Pink, S Lane, DA Hughes
Pharmacoeconomics 30 (5), 413-429, 2012
202012
Comparing generic and condition-specific preference-based measures in epilepsy: EQ-5D-3L and NEWQOL-6D
B Mulhern, J Pink, D Rowen, S Borghs, T Butt, D Hughes, A Marson, ...
Value in Health 20 (4), 687-693, 2017
152017
Psychometric properties of patient reported outcome measures (PROMs) in patients diagnosed with acute respiratory distress syndrome (ARDS)
HA Shah, M Dritsaki, J Pink, S Petrou
Health and quality of life outcomes 14 (1), 15, 2016
152016
Cost effectiveness of HPV vaccination: a systematic review of modelling approaches
J Pink, B Parker, S Petrou
Pharmacoeconomics 34 (9), 847-861, 2016
142016
Economic and health-related quality of life outcomes of whiplash associated disorders
J Pink, S Petrou, E Williamson, M Williams, SE Lamb
Spine 41 (17), 1378-1386, 2016
112016
Properties of patient-reported outcome measures in individuals following acute whiplash injury
J Pink, S Petrou, E Williamson, M Williams, SE Lamb
Health and quality of life outcomes 12 (1), 38, 2014
112014
Court R., McCarthy N., Sutcliffe P., Clarke A. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses …
P Auguste, A Tsertsvadze, J Pink
BMC Infect. Dis 17 (1), 200, 2017
102017
A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups
P Auguste, A Tsertsvadze, R Court, J Pink
Tuberculosis 99, 81-91, 2016
102016
Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK
S Datta, J Pink, GF Medley, S Petrou, S Staniszewska, M Underwood, ...
BMC infectious diseases 19 (1), 552, 2019
82019
The system can't perform the operation now. Try again later.
Articles 1–20